U.S. Markets close in 2 hrs 25 mins

Corporate News Blog - Valeant Pharma Completes Sale of its Obagi Medical Products Business

Research Desk Line-up: Bio-Path Post Earnings Coverage

LONDON, UK / ACCESSWIRE / November 13, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Valeant Pharmaceuticals International, Inc. (NYSE: VRX) ("Valeant"), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=VRX. The Company announced on November 10, 2017, that it has completed the sale of the Obagi Medical Products business for $190 million in cash to Haitong International Zhonghua Finance Acquisition Fund I, L.P. and its affiliate Obagi Cosmeceuticals, LLC. For immediate access to our complimentary reports, including today's coverage, register for free now at:


Discover more of our free reports coverage from other companies within the Drug Delivery industry. Pro-TD has currently selected Bio-Path Holdings, Inc. (NASDAQ: BPTH) for due-diligence and potential coverage as the Company announced on November 09, 2017, its financial results for Q3 2017 which ended on September 30, 2017 and also provided an update on recent corporate developments. Tune in to our site to register for a free membership, and be among the early birds that get our report on Bio-Path when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on VRX; also brushing on BPTH. Go directly to your stock of interest and access today's free coverage at:



Overview of the Obagi Medical Products Business

Obagi Medical Products is a global specialty pharmaceutical company founded by leading skin care experts in 1988. Valeant had acquired the Obagi business for approximately $344 million in 2013. The Obagi Medical Products unit comprises skin-care products, which have been specifically designed to help minimize premature skin aging, skin damage, and hyperpigmentation. These products are mostly available at dermatologists, plastic surgeons, and medical spas. Revenue and adjusted earnings before interest, tax, depreciation, and amortization (EBITDA), non-GAAP, for the Obagi business for the full-year 2017 is estimated to be around $85 million and $30 million, respectively. Valeant announced its plans to sell Obagi in July 17, 2017, and it completed the sale on November 10, 2017.

Obagi Sold to Industry Veterans

  • The buyer for the Obagi Medical Products business is a fund managed by a limited partnership that includes industry veterans China Regenerative Medicine International Ltd (CRMI) and Haitong International Securities Group, both of which are headquartered in Hong Kong.
  • China Regenerative Medicine International is engaged in the research, development, and commercialization of innovative bio-medical, healthcare products, and medical techniques.
  • CRMI operates seven production plants in Mainland China and Hong Kong and its business is organized across four strategic areas comprising of tissue engineering, cell therapy, cosmetics, and hospital management.

Valeant to Use Sales Proceeds to Repay Debts

  • Out of the total sales proceeds of $190 million, Valeant will use $180 million to repay term loan debt under its Senior Credit Facility. The divestiture of non-core assets would help Valeant streamline its product portfolio and focus on core areas of dermatology.
  • In this regard, Joseph C. Papa, Chairman and CEO at Valeant, highlighted that with the closing of the Obagi deal, the Company has decreased its total debt by over $6 billion, since the end of the first quarter of 2016. He reaffirmed that his team would continue to work diligently to focus on the core businesses and create greater value for shareholders, customers, and most importantly, patients.
  • However, analysts believe that the Company still remains highly leveraged. A net debt of around $26 billion and an expected adjusted EBITDA of around $3.6 billion for fiscal 2017 still leaves the Company stretched at 7.2 times.

Financial and Legal Advisors

For this transaction, Morgan Stanley & Co. LLC served as the financial advisor to Valeant, while Norton Rose Fulbright acted as its legal advisor.

Last Close Stock Review

On Friday, November 10, 2017, the stock closed the trading session at $15.38, marginally rising 0.20% from its previous closing price of $15.35. A total volume of 19.96 million shares have exchanged hands, which was higher than the 3-month average volume of 12.34 million shares. Valeant Pharma's stock price rallied 11.21% in the last one month, 11.69% in the past three months, and 8.54% in the previous six months. Furthermore, since the start of the year, shares of the Company have gained 5.92%. The stock currently has a market cap of $5.33 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily